cyclopropanecarboxylic acid 1-hydroxy-2,2,6,6-tetramethyl-piperidin-4-yl ester hydrochloride | 627085-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: cyclopropanecarboxylic acid 1-hydroxy-2,2,6,6-tetramethyl-piperidin-4-yl ester hydrochloride
• 英文别名: 1-hydroxy-4-cyclopropanecarbonyloxy-2,2,6,6-tetramethylpiperidine hydrochloride；1-hydroxy-4-cyclopropanecarbonyloxy-2,2,6,6-tetramethylpiperidine hydrocloride；1-hydroxy-4-cyclopropylcarbonyloxy-2,2,6,6-tetramethylpiperidine hydrochloride；N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)cyclopropanecarboxamide；OT-551 hydrochloride；(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) cyclopropanecarboxylate;hydrochloride
• CAS: 627085-15-8
• 化学式: C₁₃H₂₃NO₃*ClH
• 分子量: 277.791
• InChiKey: BGEXDXBTNACMOP-UHFFFAOYSA-N

物化性质

• 熔点：
  224-228 °C (decomp)

计算性质

• 辛醇/水分配系数(LogP)：
  2.77
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  阻聚剂701 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 2.08h， 生成 cyclopropanecarboxylic acid 1-hydroxy-2,2,6,6-tetramethyl-piperidin-4-yl ester hydrochloride
  参考文献：
  名称：

  [EN] AMELIORATION OF CATARACTS, MACULAR DEGENERATION AND OTHER OPHTHALMIC DISEASES
  [FR] AMELIORATION DE LA CATARACTE, DE LA DEGENERESCENCE MACULAIRE ET AUTRES MALADIES OPHTALMIQUES

  摘要：

  公开号：

  WO2005055926A3

文献信息

• Drug Resistance Reversal In Neoplastic Disease
  申请人：Patil Ghanshyam

  公开号：US20080200405A1

  公开（公告）日：2008-08-21

  The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.

  本发明涉及用于阻止或逆转肿瘤性疾病化疗耐药效应的化合物、组合物和方法。具体描述了羟胺的使用。
• Amelioration of the development of cataracts and other ophthalmic diseases
  申请人：——

  公开号：US20040002461A1

  公开（公告）日：2004-01-01

  Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: 1 where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  用于阻止白内障或黄斑变性发展的眼科可接受的组合物，包括药学上可接受的载体或稀释剂和具有以下公式的化合物：1其中R1和R2独立地为H或C1到C3烷基；R3和R4独立地为C1到C3烷基；且其中R1和R2一起取代，或R3和R4一起取代，或两者都可能是环烷基；R5为H，OH或C1到C6烷基；R6为C1到C6烷基，烯基，炔基或取代的烷基或烯基；R7为C1到C6烷基，烯基，炔基或取代的烷基或烯基；或者其中R6和R7，或R5，R6和R7一起形成具有3到7个原子的环烷基或杂环烷基。
• Amelioration of cataracts, macular degeneration and other ophthalmic diseases
  申请人：Matier L. William

  公开号：US20050131025A1

  公开（公告）日：2005-06-16

  Ophthalmically acceptable compositions used in arresting the development of cataract, presbyopia, macular degeneration and other retinopathies, glaucoma, uveitis and various corneal disorders are disclosed. The compositions are also useful as a prophylactic treatment to prevent or delay development of age-related ocular disorders, which include cataracts, presbyopia, glaucoma and macular degeneration. The compositions comprise a pharmaceutically acceptable carrier or diluent and at least one compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  本发明涉及可用于阻止白内障、老视、黄斑变性和其他视网膜病变、青光眼、葡萄膜炎以及各种角膜疾病的眼科可接受的组合物。该组合物还可用作预防性治疗，以预防或延迟年龄相关的眼部疾病的发展，包括白内障、老视、青光眼和黄斑变性。该组合物包括一种药用可接受的载体或稀释剂和至少一种具有以下式子的化合物：其中R1和R2独立地为H或C1到C3烷基；R3和R4独立地为C1到C3烷基；而R1和R2一起取代，或R3和R4一起取代，或两者都可以是环烷基；R5为H、OH或C1到C6烷基；R6为C1到C6烷基、烯基、炔基或取代的烷基或烯基；R7为C1到C6烷基、烯基、炔基或取代的烷基或烯基，或者R6和R7，或者R5、R6和R7一起形成一个具有3到7个原子的环烷或杂环。
• Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases
  申请人：Matier William L.

  公开号：US20130131052A1

  公开（公告）日：2013-05-23

  Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  眼科可接受的组合物，用于阻止白内障或黄斑变性的发展，包括一种药学可接受的载体或稀释剂和一种具有以下化学式的化合物：其中R1和R2分别为H或C1到C3烷基；R3和R4分别为C1到C3烷基；且其中R1和R2，一起取或R3和R4，一起取或两者都可以是环烷基；R5为H，OH或C1到C6烷基；R6为C1到C6烷基，烯基，炔基或取代的烷基或烯基；R7为C1到C6烷基，烯基，炔基或取代的烷基或烯基，或者其中R6和R7，或R5，R6和R7一起形成具有3到7个原子的碳环或杂环。
• WO2008/103613
  申请人：——

  公开号：——

  公开（公告）日：——